{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:34:50Z","timestamp":1772447690080,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The risk of wound healing complications (WHCs) and the early use of mammalian target of rapamycin inhibitors after kidney transplantation (KT) have not been fully addressed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>The NEVERWOUND study is a 3-month, multicenter, randomized, open-label study designed to evaluate whether a delayed (ie, 28 \u00b1 4 d posttransplant) immunosuppression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately after KT. Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft survival rates, and renal function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Overall, 394 KT recipients were randomized to receive immediate (N = 197) or delayed (N = 197) EVR after KT. At 3 months, WHC-free rates in the immediate EVR versus delayed EVR arm, considering the worst- and best-case scenario approach, were 0.68 (95% confidence interval [CI], 0.62-0.75) versus 0.62 (95% CI, 0.55-0.68) (log-rank <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.56) and 0.70 (95% CI, 0.64-0.77) versus 0.72 (95% CI, 0.65-0.78) (log-rank <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.77), respectively. The 3- and 12-month treatment failure rates, delayed graft function and renal function, and patient and graft survival were not different between the arms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The early introduction of EVR after KT did not increase the risk of WHC, showing good efficacy and safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002851","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T21:36:31Z","timestamp":1563744991000},"page":"374-386","source":"Crossref","is-referenced-by-count":9,"title":["A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study)"],"prefix":"10.1097","volume":"104","author":[{"given":"Tommaso Maria","family":"Manzia","sequence":"first","affiliation":[{"name":"Fondazione Policlinico Tor Vergata, Dipartimento Scienze Chirurgiche, Universit\u00e0 degli Studi di Roma Tor Vergata, Roma, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Carmellini","sequence":"additional","affiliation":[{"name":"AOU Senese, Siena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Todeschini","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Specialistica diagnostica e sperimentale, Universit\u00e0 di Bologna, Bologna, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Secchi","sequence":"additional","affiliation":[{"name":"Vita Salute San Raffaele University, Milano, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Sandrini","sequence":"additional","affiliation":[{"name":"AO Spedali Civili, Brescia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Minetti","sequence":"additional","affiliation":[{"name":"AOU Careggi, Firenze, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Furian","sequence":"additional","affiliation":[{"name":"AOU di Padova, Padova, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gionata","family":"Spagnoletti","sequence":"additional","affiliation":[{"name":"PU A.Gemelli, Roma, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[{"name":"POU S.Salvatore, L\u2019Aquila, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Benedetto","family":"Piredda","sequence":"additional","affiliation":[{"name":"AO G.Brotzu, Cagliari, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Cappelli","sequence":"additional","affiliation":[{"name":"AOUP di Modena, Modena, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GIuseppe","family":"Tisone","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Tor Vergata, Dipartimento Scienze Chirurgiche, Universit\u00e0 degli Studi di Roma Tor Vergata, Roma, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 3","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice--renal transplantation.","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 25","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ctr.12156","article-title":"Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.","volume":"27","author":"Nashan","year":"2013","journal-title":"Clin Transplant"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial.","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.transproceed.2008.05.047","article-title":"Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.","volume":"40","author":"Carmellini","year":"2008","journal-title":"Transplant Proc"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.transproceed.2010.05.036","article-title":"Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review.","volume":"42","author":"Ponticelli","year":"2010","journal-title":"Transplant Proc"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: a review of its use in renal and cardiac transplantation.","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transpl Int"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0041-1345(98)01885-5","article-title":"SDZ RAD inhibits cold ischemia-induced vascular remodeling.","volume":"31","author":"Schuurman","year":"1999","journal-title":"Transplant Proc"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth.","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1164\/ajrccm.163.2.2006093","article-title":"40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats.","volume":"163","author":"Nishimura","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.carrev.2006.05.001","article-title":"Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries.","volume":"7","author":"Waksman","year":"2006","journal-title":"Cardiovasc Revasc Med"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0041-1345(98)00590-9","article-title":"Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model.","volume":"30","author":"Cole","year":"1998","journal-title":"Transplant Proc"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000072016.13090.4E","article-title":"Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study.","volume":"76","author":"Troppmann","year":"2003","journal-title":"Transplantation"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/01.ju.0000121441.76094.6f","article-title":"The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation.","volume":"171","author":"Goel","year":"2004","journal-title":"J Urol"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/00007890-200209270-00012","article-title":"Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients.","volume":"74","author":"Langer","year":"2002","journal-title":"Transplantation"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1034\/j.1600-6143.2003.00185.x","article-title":"Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation.","volume":"3","author":"Valente","year":"2003","journal-title":"Am J Transplant"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/01.TP.0000123082.31092.53","article-title":"Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus.","volume":"77","author":"Dean","year":"2004","journal-title":"Transplantation"},{"issue":"5 Pt 1","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1600-6143.2006.01282.x","article-title":"Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.","volume":"6","author":"Kuppahally","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.healun.2007.08.014","article-title":"Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.","volume":"27","author":"Zuckermann","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1097\/TP.0000000000001432","article-title":"Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation.","volume":"100","author":"Fine","year":"2016","journal-title":"Transplantation"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/TP.0b013e318192dd56","article-title":"A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.","volume":"87","author":"Tiong","year":"2009","journal-title":"Transplantation"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1432-2277.2010.01094.x","article-title":"Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.","volume":"23","author":"Dantal","year":"2010","journal-title":"Transpl Int"},{"key":"R29-20231002","first-page":"1177","article-title":"Childhood urosepsis.","volume":"59","author":"Lich","year":"1961","journal-title":"J Ky Med Assoc"},{"key":"R30-20231002","first-page":"286","article-title":"Congenital vesico-ureteral reflux.","volume":"30","author":"Gregoir","year":"1962","journal-title":"Acta Urol Belg"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/diacare.25.6.951","article-title":"The American Diabetes Association and World Health Organization classifications for diabetes: their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese-American men.","volume":"25","author":"Rodriguez","year":"2002","journal-title":"Diabetes Care"},{"key":"R32-20231002","first-page":"79","article-title":"Relationship between post-kidney transplantation antithymocyte globulin therapy and wound healing complications.","volume":"3","author":"Pourmand","year":"2012","journal-title":"Int J Organ Transplant Med"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/TP.0000000000001945","article-title":"Optimizing the safety profile of everolimus by delayed initiation in de novo heart transplant recipients: results of the prospective randomized study EVERHEART.","volume":"102","author":"Potena","year":"2018","journal-title":"Transplantation"},{"key":"R34-20231002","first-page":"649","article-title":"The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.","volume":"5","author":"Barsoum","year":"2007","journal-title":"Exp Clin Transplant"},{"key":"R35-20231002","first-page":"59","article-title":"Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.","volume":"6","author":"Boratynska","year":"2008","journal-title":"Exp Clin Transplant"},{"key":"R36-20231002","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1111\/ctr.12223","article-title":"Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.","volume":"27","author":"Cooper","year":"2013","journal-title":"Clin Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:07:05Z","timestamp":1696223225000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002851","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}